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Abstract
For over 30 years, HIV/AIDS has wreaked havoc in the world. In the absence of an effective vaccine for HIV, development of
new anti-HIV agents is urgently needed. We previously identified the antiviral activities of the scorpion-venom-peptide-
derived mucroporin-M1 for three RNA viruses (measles viruses, SARS-CoV, and H5N1). In this investigation, a panel of
scorpion venom peptides and their derivatives were designed and chosen for assessment of their anti-HIV activities. A new
scorpion venom peptide derivative Kn2-7 was identified as the most potent anti-HIV-1 peptide by screening assays with an
EC50 value of 2.76 mg/ml (1.65 mM) and showed low cytotoxicity to host cells with a selective index (SI) of 13.93. Kn2-7 could
inhibit all members of a standard reference panel of HIV-1 subtype B pseudotyped virus (PV) with CCR5-tropic and CXCR4-
tropic NL4-3 PV strain. Furthermore, it also inhibited a CXCR4-tropic replication-competent strain of HIV-1 subtype B virus.
Binding assay of Kn2-7 to HIV-1 PV by Octet Red system suggested the anti-HIV-1 activity was correlated with a direct
interaction between Kn2-7 and HIV-1 envelope. These results demonstrated that peptide Kn2-7 could inhibit HIV-1 by direct
interaction with viral particle and may become a promising candidate compound for further development of microbicide
against HIV-1.
Citation: Chen Y, Cao L, Zhong M, Zhang Y, Han C, et al. (2012) Anti-HIV-1 Activity of a New Scorpion Venom Peptide Derivative Kn2-7. PLoS ONE 7(4): e34947.
doi:10.1371/journal.pone.0034947
Editor: Alexander M. Cole, University of Central Florida College of Medicine, United States of America
Received December 17, 2011; Accepted March 7, 2012; Published April 19, 2012
Copyright:  2012 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was financially supported by the National Natural Science Foundation of China (NSFC) (No. 30670097 to HY), the National Basic Research
Program of China (973 Program) (Nos. 2005CB522903, 2010CB530100, and 2012CB518904), and the National S&T Major Project on Major Infectious Diseases
(Nos. 2008ZX10001-010, 2012ZX10001-008) from the Ministry of Science and Technology of the People’s Republic of China. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: zjcao@whu.edu.cn (ZC); hmyan@wh.iov.cn (HY)
Introduction
Nearly 34 million people were living with human immunode-
ficiency virus (HIV) at the end of 2010 in the globe [1] and half of
them were women. Unfortunately, there are still no effective
vaccine or other countermeasure to eliminate HIV transmission
[2]. The Merck STEP [3] and the Thai RV144 HIV vaccine [4]
trials confirmed that we still have a long way to go before
developing a prophylactic HIV vaccine. Meanwhile, HIV virus
spreads fast and the HIV/AIDS pandemic still stands as a serious
public health problem worldwide [1]. Current situation clearly
indicates the necessity of developing new anti-HIV agents which
can be used for prevention of HIV/AIDS dissemination.
HIV-1 initially infects T cells through CD4 receptor [5] and
either of the two chemokine co-receptors CXCR4 (X4) or CCR5
(R5) (or both) [6,7,8]. It has been suggested that R5 is the major
co-receptor involved in sexual transmission of HIV-1 [6]. Some
microbicides tested can indeed inhibit infection by X4-tropic HIV-
1 but insufficiently inhibit R5-tropic HIV-1 to the same extent
[9,10]. SPL7013 is a dendrimer which had HIV-1 virucidal
activity against X4 and R5X4 HIV-1 strains but not R5 virus
strains [10]. Effectiveness, safety and broad spectrum are very
important to an anti-HIV microbicide. The chemokine analogue
PSC-RANTES had strong inhibition activity at R5-tropic HIV
strains but might induce local inflammation [11]. The sulfonated
polymer PRO2000 is safe but cannot provide efficacious
protection against sexual HIV transmission [12]. Polyanioun had
been suggested as potential microbicides [13,14,15]. Unfortunate-
ly, a recent phase III trial of cellulose sulfate was terminated
because of its increasing rate of HIV infection than women using a
placebo [16]. Therefore, more sources of antiviral reagent to
prevent HIV-1 transmission are needed for efficient protection of
our body from HIV infection.
Natural antimicrobial peptides (AMPs) are widely expressed and
rapidly induced on epithelial surfaces to repel invasion from
diverse infectious agents including bacteria, viruses, fungi and
parasites [17,18]. So far, more than 1700 AMPs of different origins
have been identified or predicted [19]. Most AMPs maintain
certain common features such as being small (10–50 amino acids),
containing positive charge of 2 to 9 and an amphipathic structure
[20,21,22,23]. Scorpion venom is a cocktail of peptides and
proteins with diverse bioactivities, which represent a tremendous
potential for use in drug design and development [24,25,26].
AMPs from scorpion venom such as hadrurin [27], scorpine [28],
opistoporins, parabutoporin [29], ISCTs [30] and mucroporin
[31] are paid more and more attention due to their biological
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viral pathogens such as junin virus, herpes simplex virus,
adenovirus, rotavirus, vaccinia virus, HCV and measles virus
[33,34,35,36,37].
We had reported previously that mucroporin cloned from the
venom of the scorpion Lychas mucronatus and its optimized
derivative mucroporin-M1 showed antimicrobial activity on
bacteria and measles virus [31,38]. Another scorpion peptide
BmKn2 which was cloned from the venom of Mesobuthus martensii
Karsch had also showed a strong antimicrobial activity against
bacteria [39]. As a further development of BmKn2 peptide, a new
peptide named Kn2-7 was designed by substituting Glycine
Alanine and Serine with Lysine or Arginine (G3K, A4R, and
S10R) to enhance the net positive charge and a-helix structure. In
this study, five scorpion venom peptides and their derivatives were
screened for their anti-HIV-1 activities, and the results showed
that three of them (mocroporin-M1, BmKn2 and Kn2-7) exhibited
potent anti-HIV-1 activity, in which Kn2-7 showed the highest
level of anti-HIV-1 activity. So, we speculated that Kn2-7 might
be a potential lead peptide and was tested for antiviral effects by
using a standard reference panel of subtype B HIV-1 pseudotyped
virus (PV) and a replication-competent strain of HIV-1 virus. The
binding assay of Kn2-7 to HIV-1 PV was performed for exploring
the related antiviral mechanism by Octet Red system.
Results
Molecular design, synthesis, purification and
characterization of the peptides
Kn2-7 (FIKRIARLLRKIF) was designed based on the peptide
sequence of BmKn2 (FIGAIARLLSKIF) to enhance the net
positive charge of the hydrophilic side. Kn2-7 peptide contains five
positive charges while BmKn2 carries only two positive charges
(Table 1). Glycine, Alanine and Serine residues of BmKn2 were
replaced with Lysine or Arginine (G3K, A4R, and S10R). The
secondary structures were predicted by PHD method [40] on the
website (http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.
pl?page=/NPSA/npsa_seccons.html), suggesting that Kn2-7 has
higher a-helix percentage than BmKn2, which are 84.62% and
76.92%, respectively. Information of mucroporin, mucroporin-M1
and mucroporin-S1 were describe by our previous study [38].
The five peptides were successfully synthesized on an Abimed
AMS 422 synthesizer by Fmoc solid-phase peptide synthesis. The
purities of all five peptides showed reliable quality of more than
95%. The molecule weights measured by mass spectrometry
(MS) were completely matched with the calculated molecule
weights of these peptides.
Kn2-7 was identified as the most effective scorpion
venom peptide against HIV-1 PV by screening assay
To assess anti-HIV activities of scorpion venom peptides,
pseudotyped virus-based assays with TZM-bl system were adopted
for the screening of anti-HIV-1 effect of different peptides. The
results showed that mucroporin-M1, BmKn2 and Kn2-7 could
significantly decrease infectivity of an HIV-1 clade B b12-resistant
pseudotyped virus CAAN5342 compare to the mucroporin,
mucroporin-S1, BSA and no-peptide virus mock control, in which
peptide Kn2-7 showed the highest level of anti-HIV-1 activity and
almost completely inhibited viral infection (Fig. 1). This gave us a
hint that peptide Kn2-7 is the most potential for developing anti-
HIV agent. Therefore, Kn2-7 peptide was chosen for further study
to clarify its anti-HIV effect. Mucroporin-S1 was chosen as a
negative control for the further study because it shows no anti-
bacterial and antiviral activity in our previous research [31] but
has similar number of amino acid with Kn2-7 peptide.
Table 1. The charge, first and predict secondary structure of scorpion venom peptides.
Peptide Amino Acid Sequence Charge Cationic(%) Structure Prediction
BmKn2 FIGAIARLLSKIF 2 15.38 chhhhhhhhhhcc
Kn2-7 FIKRIARLLRKIF 5 38.46 chhhhhhhhhhhc
mucroporin LFGLIPSLIGGLVSAFK 1 5.88 cccchhhhhhhhhhhhc
mucroporin-M1 LFRLIKSLIKRLVSAFK 5 29.41 chhhhhhhhhhhhhhhc
mucropotin-S1 SLIGGLVSAFK 1 9.09 ccccccceccc
h: alpha helix, c: random coil, e: extended strand.
doi:10.1371/journal.pone.0034947.t001
Figure 1. Kn2-7 was the most effective peptide against HIV-1
PV by screening assay. The antiviral effect of the peptides against
HIV-1 PV was performed by TZM-bl detection systems as described in
Materials and Methods. Briefly, 10 mg/ml of peptides were incubated
with 200 TCID50 of HIV-1 PV for 1 h at 37uC and then added to TZM-bl
cells. The luciferase activity was measured in a 96-well black solid plate
by Turner Biosystems Modulus II microplate reader 48 h later.
Significant reduction in the RLU value of groups treated by different
peptides compared to virus group in which cells were exposed to BSA
are denoted by a * (p,0.05), ** (p,0.01), and *** (p,0.001). Data are
expressed as mean 6 SD of three replicate samples.
doi:10.1371/journal.pone.0034947.g001
Anti-HIV-1 Activity of a Venom Peptide Kn2-7
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34947Kn2-7 acted sensitively and rapidly against HIV-1 PV
To confirm whether anti-HIV-1 activity of Kn2-7 was
dependent on concentration, several concentrations of Kn2-7
anti-HIV-1 activity were measured by pseudotyped virus-based
assays with TZM-bl detection system. As shown in Fig. 2A, the
antiviral-activity of Kn2-7 against HIV-1 PV was in a dose-
dependent manner and an inhibition of 40.1% was achieved at a
concentration of 2 mg/ml and its EC50 value was calculated as
2.76 mg/ml. Up to 98.7% inhibition could be achieved when
concentration rose to 16 mg/ml.
To determine the effective time needed for Kn2-7 to act on
HIV-1 PV, 3 mg/ml peptide was incubated with 200 TCID50 of
HIV-1 PV for 3 min, 10 min, 30 min, 60 min and 90 min,
respectively. As shown in Fig. 2B, from 3 min to 60 min, the
longer time treatment, the higher inhibition was achieved but no
significant difference was observed between 60 min treatment
group and 90 min treatment group. The inhibition could be up to
42.3% when Kn2-7 was incubated with HIV-1 PV for only 3 min.
Therefore, the time needed for Kn2-7 to act on HIV-1 PV was
very short and the activity peaked at the time point of 60 min.
According to this result, the concentration of 3 mg/ml (nearby
the EC50 value) and 60 min treatment were chosen for further
assay of Kn2-7 peptide on anti-HIV-1 PV activity in the following
experiments.
The inhibitory effect of Kn2-7 was selective to HIV-1 PV
To distinguish selective antiviral activity from nonselective
cytotoxicity, we tested the cytotoxicity of the peptides on TZM-bl
cells. TZM-bl cells were treated with several concentrations of
Kn2-7 peptide for 24 hours and the viability of TZM-bl cells was
measured using the MTS assay [41]. The absorbance was
measured at 490 nm using an ELISA plate reader and the CC50
value were calculated by SPSS. As shown in Table 2, CC50 of
Kn2-7 on TZM-bl cells was 38.46 mg/ml, which is 13.93 times
over the EC50 value. Therefore, the antiviral activity of the peptide
Kn2-7 against HIV-1 does not result from the cytotoxicity of the
peptide on TZM-bl cells.
Kn2-7 directly targeted HIV-1 PV
In order to gain some insight into the mechanism of anti-HIV-1
activity of Kn2-7, the interaction time and order among Kn2-7,
HIV-1 PV and TZM-b1 cells were varied by four different ways
described in Materials and Methods. Mucroporin-S1 were
prepared in the same manner and set as mock group. As shown
in Fig. 3, Kn2-7 incubating with HIV-1 PV for 1 h before
inoculating to TZM-b1 cells (peptide/virus pre-incubation group)
showed prominent inhibitory effect, agreed with the results above.
Although in a low degree, Kn2-7 and HIV-1 PV adding to cells
simultaneously but without pre-incubation (peptide/virus mixture
group) also showed a significant inhibition. However, neither the
peptide pretreated group, in which TZM-bl cells were pre-treated
with Kn2-7 for 1 h, nor the infection first group, in which TZM-bl
cells were infected with HIV-1 PV first and then treated with Kn2-
7 showed any antiviral effect (Fig. 3).
Based on the results of four treatment modes of Kn2-7, we
assumed that the anti-HIV activity of Kn2-7 attributed to its
interaction with HIV-1 viral particle directly. To confirm the
hypothesis, a binding assay based on Biolayer Interferometry was
performed to study the interaction between Kn2-7 and HIV-1 PV.
HIV-1 PV was loaded to APS biosensor and the sensor tip was
transferred to Kn2-7 or mucroporin-S1 with concentration of
10 mg/ml or 40 mg/ml. Expectedly, we observed rapid direct
binding between HIV-1 PV and Kn2-7 and the binding capacity
of 40 mg/ml Kn2-7 was stronger than that of 10 mg/ml.
Mucroporin-S1 showed no significant binding with HIV-1 PV
(Fig. 4). Therefore, Kn2-7 peptide executes anti-HIV-1 activity by
direct targeting HIV-1 particle.
Figure 2. Dose- and time-dependent effects of Kn2-7 peptide against HIV-1 PV. (A) For dose-dependent effect experiments, serial dilution
from 0.25 mg/ml to 30 mg/ml of Kn2-7 and mucroporin-S1 were incubated with 200 TCID50 HIV-1 PV for 1 h at 37uC and then added to TZM-bl cells,
respectively. (B) For time-dependent effect experiments, 3 mg/ml of Kn2-7 and mucroporin-S1 were incubated with 200 TCID50 of HIV-1 PV for 3 min,
10 min, 30 min, 60 min and 90 min, respectively. The viruses treated without any peptide were used as the control. Data are presented as mean 6
SD of three replicate samples for one representative experiment.
doi:10.1371/journal.pone.0034947.g002
Table 2. Anti-HIV-1 PV activities and cytotoxicity of Kn2-7




Kn2-7 2.76 38.46 13.93
mucroporin-S1 I .100
EC50: peptide concentration required to reduce virus infection by 50%; CC50:
peptide concentration required to reduce cell viability by 50%; SI (selectivity
index)=CC50/EC50; I: inactive.
aAll the data represent mean values for at least three independent experiments.
doi:10.1371/journal.pone.0034947.t002
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To define whether the anti-viral effect of Kn2-7 peptide against
HIV-1 PV is broad-spectrum or not, the Kn2-7 (3 mg/ml and
10 mg/ml) against a standard reference panel of HIV-1 subtype B
isolates were measured using TZM-bl detection system and
mucroporin-S1 was used as the negative control. Inhibitions were
calculated compared to the HIV-1 PV control group. 3 mg/ml and
10 mg/ml of Kn2-7 peptide showed comparable antiviral
potencies against 13 strains of HIV-1 subtype B PV including 12
R5-tropic (6535, QH0692, SC422661, PVO, TRO, AC10,
PHPA4259, THRO4156, REJO4551, TRJO4551, WITO4160,
CAAN5342) and 1 X4-tropic (NL4-3). The negative control of
mucroporin-S1 show no inhibitory effect at corresponding
concentrations (3 mg/ml of mucroporin-S1 data not shown)
(Fig. 5). Consequently, Kn2-7 peptide had a broad-spectrum
antiviral activity against HIV-1 PV regardless of tropism.
Kn2-7 had anti-viral effect against replication-competent
HIV-1 virus
To confirm the potent inhibition of Kn2-7 to HIV-1, a
replication-competent HIV-1 virus was also adopted for the anti-
HIV activity assay. Serial dilutions of Kn2-7 or mucroporin-S1
were incubated with 20 ml X4-tropic proviral DNA (pKS242)
derived HIV-1 virus (15 ng p24) for 1 h at 37uC and then infected
CEM6174 cells for 17 days. Supernatant and cell samples were
collected at day 7, 12, 13, 14, 15, 16 and 17. P24 antigen
expression was analyzed by ELISA and infectivity was further
detected by TZM-bl detection system. 10 mg/ml and 15 mg/ml of
Kn2-7 suppressed p24 expression completely from 7
th day to 17
th
day in infected cell (Fig. 6A) as well as in supernatant (Fig. 6B).
5 mg/ml of Kn2-7 suppressed p24 expression in cell sample in
early stage (7
th day to 14
th day), but not in the later time points,
with the value of p24 rose at 15
th day, till to 17
th day (Fig. 6A). The
p24 antigen level in supernatants showed the same trend as that of
cell samples by 5 mg/ml of Kn2-7, but with a delayed reaction
(Fig. 6B). The negative control peptide, mucroporin-S1, did not
show any inhibitory effect. To further determine antiviral activity
of Kn2-7, the above samples was added to TZM-bl cells for
detection of their infectivity. Luciferase activities of infected TZM-
bl cells were measured after 48 h incubation. Similar trends of
inhibitory effect were observed (Fig. 6C). However, 15 mg/ml of
Kn2-7 inhibited virus replication completely but 10 mg/ml of
Kn2-7 did not (Fig. 6C) while both 10 and 15 mg/ml of Kn2-7
showed completed suppression by p24 assay (Fig. 6A, 6B). The
results further demonstrated that the Kn2-7 can inhibit HIV
infectivity and its consequent replication. To rule out potential
inhibitions attributable to cytotoxicity to host cells, the cytotoxicity
of the peptides on CEM6174 cells were measured by using the
MTS assay from 5 mg/ml to 100 mg/ml and the CC50 value of
Figure 3. Directly inactivated mechanism of Kn2-7 peptide to
HIV-1 PV. Four action modes of treatment between peptides with HIV-
1 PV were carried out. (1) Peptide pretreated group, TZM-bl cells were
pretreated with 10 mg/ml peptide at 37uC for 1 h and then treated with
HIV-1 PV. (2) Infection first group, cells were infected with HIV-1 PV first
by inoculating at 37uC for 1 h and then treated with 10 mg/ml peptide.
(3) Peptide/virus mixture group, cells were treated with mixture of HIV-1
PV and 10 mg/ml peptides immediately after mix but without
inoculation. (4) Peptide/virus pre-incubation group, cells were infected
with mixture of HIV-1 PV and 10 mg/ml peptides pre-incubating at 37uC
for 1 h. The inhibitory effects of different groups were determined in
TZM-bl detection system. Significant reduction in the RLU value of Kn2-
7 treatment group compared with that of mucoporin-S1 treatment
group are denoted by a * (p,0.05), ** (p,0.01), and *** (p,0.001).
doi:10.1371/journal.pone.0034947.g003
Figure 4. Direct binding of peptide Kn2-7 to HIV-1 PV. HIV-1 PV was bound and analyzed, in parallel, by five Octet APS sensors. APS sensors
were pre-wet for 120 s, and then coupled with 200 ml HIV-1 PV for 300 s. After clearance of unabsorbed PV, APS sensors were associated with 10 mg/
ml and 40 mg/ml of Kn2-7 or mucroporin-S1 for 900 s (Measured in nanometers).
doi:10.1371/journal.pone.0034947.g004
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antiviral activity of Kn2-7 against HIV-1 does not result from the
cytotoxicity of the peptide on CEM6174 cells.
In brief, the scorpion venom peptide derivative Kn2-7 not only
significantly inhibits HIV-1 PV, but also has antiviral effect against
replication-competent HIV-1 virus with broad-spectrum by direct
interaction with viral particle and may become a promising
candidate compound for further development of anti-HIV-1
agent.
Figure 5. Broad-spectrum antiviral activity of Kn2-7 against 13 strains of HIV-1 subtype B PV. The inhibitory effect of the peptide was
determined in TZM-bl luciferase detection system. Briefly, 3 mg/ml and 10 mg/ml of Kn2-7 was incubated with different strains of HIV-1 PV (200
TCID50) for 1 h at 37uC and then added to TZM-bl cells. The group treated with mucroporin-S1 and without any peptide in the same manner served
as the negative and background control, respectively.
doi:10.1371/journal.pone.0034947.g005
Figure 6. Antiviral activity of Kn2-7 against a replication-competent HIV-1 virus. Three dilutions of Kn2-7 or mucroporin-S1 were
incubated with HIV-1 virus for 1 h at 37uC, and then were added to CEM6174 cells in 12-well plates in duplicates for 17 days. Samples were collected
at day 7, 12, 13, 14, 15, 16, and 17 after infection and p24 protein concentration of the cells and supernatants were detected by ELISA. The infectivity
was measured by TZM-bl detection luciferase assay. (A) CEM6174 cells samples were measured for p24 protein by ELSIA. (B) CEM6174 supernatant
samples were measured for p24 protein by ELSIA. (C) Samples were detected for infectivity by TZM-bl detection system.
doi:10.1371/journal.pone.0034947.g006
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For three decades, HIV/AIDS has wreaked havoc on the
population of the world. Although the number of new infections
has been falling, levels of new infections overall are still high. The
vast majority of people newly infected with HIV are infected
during unprotected sexual intercourse [42]. The quest for effective
microbicide and drug to prevent initial HIV-1 infection and treat
AIDS patients is essential for countering the spread of the diseases
worldwide when there is no effective prophylactic HIV vaccine
available at present. Tremendous efforts have been directed
towards development of effective anti-HIV-1 microbicides, which
are defined as products that can be applied topically for the
prevention of HIV-1 and other sexually transmitted infections by
creating chemical, biological and-/or physical barriers. An
effective microbicide against HIV should be efficient with anti-
HIV-1 activity, safe with low cytotoxicity to host cells and broad-
spectrum against both R5-tropic and X4-tropic HIV-1 [6,43,44].
For satisfying all the criteria above, more resources of possible
anti-HIV-1 reagents should be explored.
In previous studies, we isolated several kinds of cationic
antimicrobial peptides from the cDNA libraries of the venomous
gland of scorpions and identified their anti-bacterial activity
against pathogens [24,31]. Recently we reported that mucroporin-
M1, one kind of modified scorpion venom peptide, can inhibit
some RNA viruses such as measles virus, SARS-CoV and
influenza H5N1 viruses [38]. In this study, we screened the anti-
HIV-1 efficacy of five scorpion venom peptides and their
derivatives. The results showed that Kn2-7, BmKn2 and
mucorporin-M1 exhibited varying degrees of antiviral effects and
among them Kn2-7 peptide was the most effective with an EC50
value of 2.76 mg/ml (Fig. 1). According to the most potent anti-
HIV-1 activity and low toxicity on TZM-bl cells and the mouse
skin model (unpublished data), Kn2-7 was chosen for further
investigation to clarify its anti-HIV-1 effect. Kn2-7 was modified
from BmKn2 by enhancing the net positive charge of the
hydrophilic side and the amphiphilic helix through amino acid
replacing (G3K, A4R, and S10R). We found Kn2-7 had higher
anti-HIV-1 activity than BmKn2, but with similar CC50 to cells
and even decreased toxicity response by the mouse skin model test
(unpublished data). So, the modification improved the specific
anti-viral activity in a certain extend. However, the mechanism
needs to study further.
Since CCR5 is the major co-receptor involved in sexual
transmission which becomes the leading infection route of HIV-
1, antiviral activity against R5-tropic HIV-1 is more important
[6,43]. Therefore, CAAN5342, a R5-tropic HIV-1 PV, the most
tolerated HIV-1 PV to monoclonal antibody B12 and 2G12 in the
standard reference panel of HIV-1 subtype B pseudotyped virus
was chosen to test the antiviral activity of Kn2-7 [45]. Kn2-7
showed potent antiviral activity against CAAN5342 in a dose- and
time-dependent manner (Fig. 2). Further studies demonstrated
that Kn2-7 was effective against HIV-1 subtype B PV regardless of
their tropism with a selective index (SI) of 13.93. It was also highly
effective to suppress replication-competent HIV-1 strain (Fig. 6).
The results demonstrated that Kn2-7 was broad-spectrum against
HIV-1 which was in accordance with our previous findings that
scorpion venom peptides are broad-spectrum biocides [24,31,38].
On the other hand, Kn2-7 was proven to be active to both cell-
free and cell-associated replication-competent HIV-1 exhibited by
its suppressing capability on infected TZM-bl cells, in which
15 mg/ml of Kn2-7 almost completely inhibited viral replication
(Fig. 6C). As shown by Cole et al., HIV-1 evolves little resistance
during continued passaging in the presence of defensins, another
kind of cationic antimicrobial peptide [46]. Kn2-7 may also
possess this particular property which can reduce the likelihood of
the emergence of resistance and the subsequent spread of
infection.
As reported earlier, scorpion venom peptides display anti-
pathogen activity by breaking bacteria directly [31,38]. We
assumed that Kn2-7 may implement the inhibition of HIV-1 with
the similar mechanism. The experiment of four different treatment
groups of Kn2-7 to HIV-1 PV, in which the viral infectivity was
inhibited only when Kn2-7 had chance to interact directly to HIV-
1 PV, gave us a hint that Kn2-7 may exert its antiviral activity by
damaging HIV virus particle itself. To clarify the presumption, we
tried the binding assay for possible interaction between Kn2-7 and
HIV-1 PV with Octet Red system by using APS sensors. The
result confirmed that Kn2-7 could directly bind to HIV-1.
However, whether viral particle could be broken by this binding
is not clear. In experiments for effective action time of Kn2-7 to
HIV-1 PV, it was observed that 3 min interaction allowed Kn2-7
showing almost maximum inhibition to HIV-1 PV (Fig. 2B). This
told us that the anti-HIV-1 activity of Kn2-7 was rapid and direct
which is similar to the action manner of mucroporin to bacteria
[31]. Barrel-stave model might explain what happened between
Kn2-7 and HIV-1 virus to some extent [47,48,49]. We may
deduce the action principles as following: once Kn2-7 encounters
with HIV-1, Kn2-7 binds to the envelope of HIV-1 directly and
immediately. The attached Kn2-7 aggregates and inserts into viral
envelope so that the hydrophobic peptide regions align with the
lipid core region and the hydrophilic peptide regions form the
interior region of the pore, with the help of positive charge of
peptide somehow. However, more investigations need to be done
for further clarification.
The epidemic of HIV-1 combined with the lack of an effective
vaccine urge us to find more new resources of antiviral agents to
help control HIV-1 transmission. In this study, a rationally
designed peptide, Kn2-7, shows potent antiviral activities against
13 strains of HIV-1 subtype B strains by direct interaction with
virus regardless of their tropism with low cytotoxicity. The data
presented here suggest that Kn2-7 is a potential microbicide
candidate against HIV-1 virus and even become a powerful anti-
HIV-1 drug component when it is conjugated with HIV-1 specific
antibodies. All in all, scorpion venom peptides can be at least
served as molecular templates for designing antiviral peptides for
HIV-1. Further pharmacokinetic, pharmacodynamic, and toxico-
logical studies in animal models are worth being conducted to
define safety parameters and application potential for the practical
use of Kn2-7 as preventive agents for HIV-1 transmission.
Materials and Methods
Molecular design, synthesis, purification and
characterization of scorpion venom peptides
BmKn2 is a 13 amino acid antimicrobial peptide which cloned
from the venom of Mesobuthus martensii Karsch [39]. Kn2-7 is an
optimizing design of BmKn2 by substituting Glycine Alanine and
Serine with Lysine or Arginine (G3K, A4R, and S10R).
Mucroporin is a 17 amino acid peptide from the venom of the
scorpion Lychas mucronatus. Mucroporin-M1 is a derivative of
mucroporin by substituting Glycine and Proline residues with
Lysine or Arginine (G3R, P6K, G10K, and G11R) [31].
Mucroporin-S1 is an 11-amino peptide by removing 6 N-terminal
amino acids from mucroporin as a control in this study.
Kn2-7 (FIKRIARLLRKIF), BmKn2 (FIGAIARLLSKIF), mu-
croporin (LFGLIPSLIGGLVSAFK), mucroporin-M1 (LFRLIK-
SLIKRLVSAFK), and mucroporin-S1 (SLIGGLVSAFK), were
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phase peptide synthesis. The purification and characterization
were carried out as described before [38]. Briefly, all peptides were
purified on a C18 column (Elite HPLC, China) using a linear
gradient and peaks were detected by the absorbance at 215 nm
and collected manually. Thereafter, peptides were lyophilized and
the purity was tested by high-performance liquid chromatography
(HPLC) and mass spectrometry.
Cells
TZM-bl cells (NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, National Institutes of Health)
are a genetically engineered HeLa cell clone that express CD4,
CCR5 and CXCR4, and was further engineered with an HIV-1-
based vector to contain Tat-responsive reporter genes for firefly
luciferase (Luc) as contributed by John Kappes and Xiaoyun Wu
[50,51]. 293 T, Vero and CEM6174 cell lines were obtained from
American Type Culture Collection (Rockville, MD, U.S.). TZM-
bl, 293 T and Vero cells were cultured in Dulbecco’s modified
Eagle’s medium (Gibco DMEM) containing 10% fetal bovine
serum (FBS, 56uC heat-inactivated, Gibco), 1% L-glutamine and
1% penicillin/streptomycin (Gibco). The cells were incubated at
37uC in a humidified atmosphere containing 5% CO2. The
CEM6174 cells were cultured in RPMI 1640 medium (Gibco)
supplemented with 10% FBS, 1% L-glutamine, and 1%
penicillin/streptomycin.
Preparation and titration of single-cycle HIV-1 PV and
replication-competent HIV-1 virus from proviral DNA
All clones for pseudotyped virus-based assays were provided by
NIH AIDS Research and Reference Reagent Program. Stocks of
Env-pseudotyped virus were produced in 293 T cells briefly as
following. 293 T cells (5610
6 cells/ml) were co-transfected with
6 mg of an Env-deficient HIV-1 backbone vector (pSG3DEnv) and
4 mg of a plasmid encoding envelope protein of one strain of HIV-
1 subtype B (6535, QH0692, SC422661, PVO, TRO, AC10,
PHPA4259, THRO4156, REJO4551, TRJO4551, WITO4160,
CAAN5342 [45,50,52], NL4-3 [53]) using Lipo2000 agent
(Invitrogen) in 6-well plates. PV-containing culture supernatants
were harvested 48 h after transfection, centrifuged, purified by
0.45 mm filter and stored at 280uC in 200 ml aliquots. The 50%
tissue culture infectious dose (TCID50) measurements were done in
triplicates using 8 serial four-fold dilutions of each HIV-1 PV. For
each dilution, every well of a 96-well culture plate was added with
100 ml diluted PV firstly and then with trypsinized TZM-bl cells
(10
4 cells in 100 ml of growth medium containing 15 mg/ml
DEAE-dextran (Sigma)). Plates were incubated at 37uCi na
humidified, 5% CO2 atmosphere for 48 h. To measure luciferase
activity, culture medium was removed, monolayers were washed
once with 200 ml PBS, and 100 ml cell culture lysis buffer
(Promega) was added to cells and incubated for 20 min at room
temperature to allow cell lysis. After that, 50 ml of cell lysate was
transferred to 96-well black solid plate (Promega) and relative
luminescence units (RLU) activity was measured by a Luciferase
Assay System according to the manufacturer’s instructions
(Promega) using Tuner Biosystems Modulus II. Samples produc-
ing relative light units (RLU).2.56background wells (containing
cells only) were scored as positive infection. An endpoint virus titer
of TCID50 was calculated by the Spearman-Karber method [54].
Except in broad-spectrum antiviral effect assay, a panel of HIV-
1 PV (R5-tropic (6535, QH0692, SC422661, PVO, TRO, AC10,
PHPA4259, THRO4156, REJO4551, TRJO4551, WITO4160,
CAAN5342) and X4-tropic (NL4-3) HIV-1 PV) was used, a R5-
tropic HIV isolate CAAN5342 was used in all other pseudotyped
virus-related experiments.
An HIV-1 subtype B, X4-tropic proviral DNA (pKS242
molecular clone) [55] was used to produce replication-competent
virus by transfecting Vero cells with Lipo2000 agent, and virus was
propagated in CEM6174 cells. Cultures were maintained and
HIV-containing CEM6174 cells and supernatant were collected.
HIV-1 replication-competent viruses were quantified by p24
concentration.
Cell viability assay
In vitro cytotoxicity test of Kn2-7 and mucroporin-S1, were
performed by 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) procedure [41].
Briefly, TZM-bl or CEM6174 cells were seeded into 96-well
plates at a density of 1610
4 cells/well in triplicates and incubated
at 37uC for 24 h. Thereafter, culture medium was replaced by
100 ml serial dilutions of the peptides (from 5 mg/ml to 100 mg/ml)
in DMEM culture, and the cells were incubated for another 24 h.
Each dilution was tested in triplicates and all the experiments were
repeated three times. Then 20 ml of CellTiter 96H AQueous One
Solution Reagent (Promega) was added to each well of the 96-well
assay plate containing 100 ml sample in culture medium. The plate
was further incubated for 2 h at 37uC in a humidified, 5% CO2
atmosphere. The absorbance was measured at 490 nm using an
ELISA plate reader (Multiskan MK3, Thermo Labsystems). The
relative cell viability (%) related to control wells containing cell
culture medium without peptide was calculated by [A] test/[A]
control6100%. The cytotoxicity of each peptide is expressed as
the 50% of cytotoxic concentration (CC50), which is the
concentration that inhibits the growth of 50% of cells relative to
non-treated control cells.
Antiviral effect assay of the peptides against HIV-1 PV
To test the antiviral effect of the peptides against HIV-1,
pseudotyped virus-based assays with TZM-bl system were
performed as described previously [56]. Briefly, 200 TCID50 of
HIV-1 PV were incubated with indicated concentration of test
scorpion venom peptides in a total volume of 100 ml for 60 min or
indicated time intervals when considered with time-course effects
at 37uC in triplicates in 96-well plates. After incubation, freshly
trypsinized TZM-bl cells (10
4 cells in 100 ml of growth medium
containing 15 mg/ml DEAE-dextran) were added to each well and
incubated for 48 h. The luciferase activities of the TZM-bl cells
were measured for antiviral activities of tested peptides, in which
virus control and blank control were set up as wells of cells plus
virus and cells only respectively.
In screening assay of anti-virus effect, 10 mg/ml peptides were
used. For the following anti-HIV-1 PV effect assay, 3 mg/ml of the
lead peptide Kn2-7 and the truncated control peptide mucro-
porin-S1 were used except for the dose-dependent effect
experiment, in which serial dilutions from 0.25 mg/ml to 30 mg/
ml were used.
In the time-dependent effect experiment, 3 mg/ml of peptides
were incubated with 200 TCID50 of HIV-1 PV for 3 min, 10 min,
30 min, 60 min, and 90 min, respectively.
Measurement of antiviral activity of the peptides against
replication-competent HIV-1 virus
Three dilutions of peptide (5 mg/ml, 10 mg/ml, and 15 mg/ml)
were incubated with HIV-1 replication-competent virus (15 ng
p24) for 1 h at 37uC. Thereafter, the compounds were added to
CEM6174 cells (10
5 cells/ml) in duplicates in 12-well plate.
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infection. Supernatant and cell samples were separated by
centrifuge 1000 rpm for 5 min (Thermo). Samples were detected
for p24 by ELISA and measured for infectivity by TZM-bl
detection systems as described above.
Action mode of the peptides to HIV-1 PV
In order to help determine the possible antiviral mechanism of
Kn2-7 peptide, four different treatment groups were designed for
comparison of the antiviral effect as following: (1) peptide
pretreated group, TZM-bl cells were pretreated with 10 mg/ml
peptide at 37uC for 1 h and then treated with HIV-1 PV; (2)
infection first group, TZM-bl cells were infected with HIV-1 PV
first by inoculating at 37uC for 1 h and then treated with 10 mg/
ml peptide; (3) peptide/virus mixture group, TZM-bl cells were
treated with mixture of HIV-1 PV and 10 mg/ml peptides
immediately after mix but without inoculation; and (4) peptide/
virus pre-incubation group, TZM-bl cells were infected with
mixture of HIV-1 PV and 10 mg/ml peptides pre-incubating at
37uC for 1 h. To compare the effects of peptide to viral infection,
TZM-bl cells were measured by luciferase activity assay after 48 h
incubation as described above. 200 TCID50 of HIV-1 PV
(CAAN5342) was used in different treatment groups. In parallel,
mucroporin-S1 control groups were set up in the same four
manners.
p24 protein detection by ELISA
For p24 protein detection, a double antibody sandwich ELISA
was used [57]. Briefly, ELISA plates (Greiner Bio-one Microplate)
were coated with rabbit anti-p24 polyclone-antibody (3 mg/ml in
carbonate buffer 0.1 M NaHCO3, 0.1 M Na2CO3, pH 9.6) at
37uC for 2.5 h. Thereafter, plates were blocked using 10% FBS in
PBS at 4uC overnight. Samples were serially diluted with PBS
containing 10% FBS and 1% (v/v) TritonX-100 and treated for
3 h at 37uC to release p24 from the HIV-1 PV particles. P24
standard samples were treated in the same way to create a
standard curve. Then treated sample dilutions were placed in wells
for 2 h at 37uC. The plates were washed 6 times with PBS
containing 0.05% Tween 20 (PBS-T). Mouse anti-p24-HRP
antibody (1:1200) was added and incubated for 1 h at 37uC and
then washed 6 times with PBS-T. 100 mlo f3 ,3 9,5 ,5 9-
tetramethylbenzidine (TMB, Sigma Aldrich) was added to each
well and incubated for 10–20 minutes at room temperature
depending on the degree of colorimetric conversion of standard
samples. The reaction was stopped with 1 M H2SO4, and the
plate was read at 450 nm and 570 nm. OD value=(OD value at
450 nm) - (OD value at 570 nm). The p24 standard curve was
drawn and a linear regression equation was made. The linear
range was from 5 pg/ml to 100 pg/ml and the p24 concentration
of the sample was computed using the equation.
Biolayer Interferomtery
Binding assays were performed in 96-well microplates at 25uC
by Octet Red system (Ferbio) [58,59]. All the measurement
processes are under computer control. The run was carried out by
placing the APS sensors in the wells and measuring changes in
layer thickness (in nanometers, nm) with time. Serial dilutions of
peptides (Kn2-7 and mucroporin-S1) were run in 200 ml volumes
under the same assay. Firstly, APS sensors were rinsed in DMEM
buffer for 120 s which served as the background buffer. Secondly,
APS sensors were coupled with 200 ml culture containing HIV-1
PV for 300 s. Thirdly, APS sensors were moved into DMEM
buffer and incubated for another 120 s to clear unabsorbed HIV-1
PV. Lastly, APS sensors were exposed to Kn2-7 or mucoporin-S1
at concentrations of 10 mg/ml or 40 mg/ml. Association was
monitored for 900 s followed by dissociation in DMEM buffer
alone for another 400 s. The standard curve was measured at the
beginning and the end of the assay to confirm that it was
reproducible and valid over the time taken to run all rows of
samples. Data were processed automatically using the Octet User
Software version 3.1.
Data analysis
The virus titer was calculated within each individual experiment
using the method of Reed and Muench [60]. All statistical analyses
were conducted using GraphPad Prism, version 5. Statistical
comparisons were conducted using the 2-tailed unpaired t test. P
values ,0.05 were considered significant. Data were presented as
one representative of at least three repeated experiments and
expressed as mean 6 standard deviation (SD) of triplicates. The
value of the TCID50,C C 50 and EC50 were analog computation by
SPSS statistical software version 13 (SPSS, Chicago, IL).
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